Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05902988 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 4, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study sites: 13 to 14v13
  2. Enrollment target: 120 to 200v12
  3. Primary completion date: Dec 2025 to Jun 2026
    • Study completion date: Jun 2026 to Dec 2026
    v11
  4. Study sites: 12 to 13v10
  5. Site details revised at 1 of 12 sitesv9
Show 7 earlier versionsHide 7 earlier versions
  1. Study sites: 11 to 12v8
  2. Study sites: 10 to 11v7
  3. Study sites: 9 to 10v6
  4. Study sites: 5 to 9v5
  5. Study sites: 2 to 5v4
  6. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date changed from estimate of Sep 2023 to Oct 18, 2023
    v3
  7. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Volastra Therapeutics, Inc.
2 trials monitored
See 1 trial at risk
Breast Cancer
5,418 trials monitored
See 296 trials at risk
Lung Cancer
4,790 trials monitored
See 263 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
3,078 trials monitored
See 172 trials at risk
and 5 more diseases
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Trial Details
NCT Number NCT05902988
Lead Sponsor Volastra Therapeutics, Inc.
Conditions
(from sponsor)		 Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma +2 more
Related terms Chromosomal Instability, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov